Middle East Regulatory Consulting — GCC Pharmaceutical & Device Regulatory Services
Specialist regulatory affairs consulting services for Middle East — covering SFDA (Saudi Arabia), MOHAP (UAE), GCC Health Ministers’ Council requirements and all major regulatory frameworks.
Middle East regulatory consulting requires specialist knowledge of a diverse and rapidly evolving regulatory landscape — spanning Saudi Arabia’s SFDA (Saudi Food and Drug Authority), UAE’s MOHAP and Dubai Health Authority, Kuwait’s Ministry of Health, Qatar’s MOPH, and other GCC regulatory bodies. The Middle East represents one of the fastest-growing pharmaceutical and medical device markets globally, with ambitious healthcare investment programmes driving regulatory capacity development across the region. At RABT Global, our GCC regulatory consulting services are delivered by specialists with in-country Middle East regulatory experience.
Regulations & Requirements — Middle East
- SFDA pharmaceutical and device regulations (Saudi Arabia)
- MOHAP / DHA regulations (UAE)
- Gulf Central Committee for Drug Registration (GCCDR)
- GCC Mutual Recognition Agreement (MRA) framework
- SASO standards and GCC technical regulations
Our Middle East Regulatory Consulting Services
SFDA regulatory consulting services — Saudi drug and device registration
UAE regulatory affairs consulting — MOHAP and DHA pharmaceutical and device registration
GCC regulatory consulting services — multi-country simultaneous registration strategy
Pharmaceutical regulatory consulting Middle East — GCC drug approval processes
Middle East regulatory affairs services — medical device registration across GCC countries
Life sciences regulatory consulting Middle East — regional regulatory strategy and market entry
Middle East regulatory strategy consulting — GCC MRA leverage for multi-market entry
Regulatory Consulting Services in Middle East
RABT Global provides specialist regulatory consulting services in Middle East — covering pharmaceutical drug registration, medical device regulatory compliance, clinical trial applications, and ongoing regulatory lifecycle management under SFDA (Saudi Arabia), MOHAP (UAE), GCC Health Ministers’ Council regulatory requirements. Our Middle East regulatory consulting team combines in-country regulatory experience with global life sciences expertise to deliver effective, efficient regulatory programmes for every client.
Middle East Regulatory Consulting — FAQs
A: The primary regulatory bodies across the GCC are: SFDA (Saudi Food and Drug Authority, Saudi Arabia), MOHAP (Ministry of Health and Prevention, UAE), DHA (Dubai Health Authority, UAE), MOH (Kuwait), MOPH (Qatar), NHRA (Bahrain), and MOH (Oman). The GCC Mutual Recognition Agreement (MRA) provides a framework for multi-market recognition, though country-specific requirements still apply. RABT Global’s Middle East regulatory consulting covers all GCC markets.
A: The GCC Drug Registration Mutual Recognition Programme allows pharmaceutical companies with registration approval from one GCC member state to use that approval as the basis for registration in other GCC countries — reducing the documentation burden and accelerating multi-market market access. RABT Global’s GCC regulatory consulting services maximise the benefit of MRA for your registration programme.
A: RABT Global brings specialist SFDA (Saudi Arabia), MOHAP (UAE), GCC Health Ministers’ Council regulatory expertise combined with a global regulatory perspective. Our Middle East regulatory consulting services are delivered by dedicated in-country regulatory specialists — ensuring accurate, up-to-date guidance on all aspects of Middle East regulatory requirements for pharmaceutical and medical device companies.
Navigate Middle East Regulatory Requirements with Confidence
Expert regulatory consulting services for Middle East. SFDA (Saudi Arabia), MOHAP (UAE), GCC Health Ministers’ Council compliance. Market access. Delivered by RABT Global’s specialist Middle East regulatory team.